Attached files
| file | filename |
|---|---|
| EX-10.1 - FIRST CHINA PHARMACEUTICAL GROUP, INC. | v211880_ex10-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
February
11, 2011
Date of
Report (Date of earliest event reported)
First
China Pharmaceutical Group, Inc.
(Exact
Name of Registrant as Specified in Charter)
|
Nevada
|
000-54076
|
74-3232809
|
||
|
(State
or Other Jurisdiction of Incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification
No.)
|
Number
504, West Ren Min Road,
Kunming
City, Yunnan Province
People’s Republic of China, 650000
(Address
of Principal Executive Offices)
852-2138-1668
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Section
5-Corporate Governance and Management
Item
5.02. Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
Effective February 11, 2011, Aidan
Hwuang resigned as a member of the Board of Directors of First China
Pharmaceutical Group, Inc. (the “Company”). The Company agreed to pay
Mr. Hwuang US$150,000 pursuant to the terms of that certain Mutual Release and
Settlement Agreement, dated February 11, 2011, by and between the Company and
Mr. Hwuang, a copy of which is attached hereto as Exhibit 10.1 and incorporated
herein by reference.
Section
9-Financial Statements and Exhibits
Item
9.01. Financial
Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
Exhibit
|
|
Number
|
Description
|
|
|
10.1
|
Mutual
Release and Settlement Agreement, dated February 11, 2011, by and between
the Company and Aidan Hwuang
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
FIRST
CHINA PHARMACEUTICAL GROUP, INC.
|
||
|
Dated:
February 17, 2011
|
By:
|
/s/ Zhen Jiang Wang
|
|
Zhen
Jiang Wang
|
||
|
Chief
Executive Officer
|
||